Rhythm's experimental drug to treat a form of obesity meets main goal in study
09/07/2025 13:07
July 9 (Reuters) - Rhythm Pharmaceuticals RYTM.O said on Wednesday that its experimental drug to treat a type of obesity met the main goal in a mid-stage study. (Reporting by Bhanvi Satija in Bengaluru; Editing by Sahal Muhammed) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand